According to a recent LinkedIn post from HistoSonics, company scientific co‑founder Dr. Zhen Xu has been named to TIME’s 2026 TIME100 Health list of influential leaders in health. The post highlights her role as co‑inventor of histotripsy and notes that her research underpins a non‑invasive approach to liver tumor destruction that avoids incisions and radiation toxicity while reportedly maintaining a low complication rate.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Xu’s ongoing work at the University of Michigan aims to extend histotripsy into additional tumor types as well as neurological and cardiovascular indications. For investors, this recognition may reinforce HistoSonics’ scientific credibility, support its positioning within the non‑invasive oncology and broader therapeutic device markets, and potentially aid in attracting clinical partners, talent, and capital as the technology scales.
As shared in the LinkedIn content, histotripsy is described as already helping thousands of patients, implying early real‑world adoption that could underpin future revenue growth if translated into broader commercial use. Inclusion on a high‑visibility health leadership list may also raise awareness among physicians and hospital systems, which could modestly improve HistoSonics’ competitive profile versus other minimally invasive or ablative treatment platforms over the medium term.